Monte Rosa Therapeutics, Inc. Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years
Monte Rosa Therapeutics, Inc. (GLUE) had Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years of $7.42 million as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Compensation Related Costs › Retirement Benefits › Defined Benefit Plan › Defined Benefit Plan, Expected Future Benefit Payment
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter · last filed 2026-03-17
- 2025-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $7.42M.
- 2024-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $4.20M.
- 2023-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $6.30M.
- 2022-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $4.24M.
| Period end | Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years |
|---|---|
| 2025-12-31 | $7.42M 10-K · filed 2026-03-17 |
| 2024-12-31 | $4.20M 10-K · filed 2025-03-20 |
| 2023-12-31 | $6.30M 10-K · filed 2024-03-14 |
| 2022-12-31 | $4.24M 10-K · filed 2023-03-16 |
| 2021-12-31 | $2.36M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |